JPRN-UMIN000043558Completed未知
Investigation of immunogenicity and persistence of the COVID-19 vaccine, background factors affecting them, and potential of the microbiomes in the oral cavity and intestinal tract as predictive markers of immunogenicity and persistence - Investigation of immunogenicity and persistence of the COVID-19 vaccine, background factors affecting them, and potential of the microbiomes in the oral cavity and intestinal tract as predictive markers of immunogenicity and persistence
Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University0 sites180 target enrollmentStarted: March 10, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 180
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Key exclusion criteria 1) Those who do not wish to be vaccinated with COVID-19 vaccine. 2) Those who have a history of COVID-19. 3) Those who are judged to be inappropriate for registration at the discretion of the doctor in charge.
Investigators
Similar Trials
Completed
Phase 3
Durability of Immunogenicity and Effectiveness of the heterologous COVID-19 vaccination in kidney transplant recipientsImmunogenicity of the vaccineEffectiveness of the vaccinehumoral immunity, cell-mediated immunity, SARS-CoV-2, immunization, immunocompromisedTCTR20220511002ational Council Researach of Thailand100
Not yet recruiting
Not Applicable
A study on immunity after Covid 19 vaccineCTRI/2021/07/034663ational Centre for Biological Science
Not yet recruiting
Phase 3
Study of immunity to flu vaccine.CTRI/2021/11/037859Christian Medical College Vellore
Completed
Phase 1
Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16IRCT20190504043464N1Iran University of Medical Sciences200
Recruiting
Phase 4
Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2prevention covidDRKS00025271niklinik Regensburg Abteilung für Hygiene und Infektiologie154